On May 23, the FDA approved a new drug intended to treat hospital-acquired pneumonia and ventilator-associated pneumonia caused by Acinetobacter baumannii-calcoaceticus, a critical bacterial pathogen.
Read the full post on Becker's Hospital Review - Healthcare News
